

Supporting information

Heat-triggered Drug Release Systems based on Mesoporous Silica Nanoparticles and Phase-change Molecules as Gatekeepers

Ji Liu, Christophe Detrembleur, Marie-Claire De Pauw-Gillet, Stéphane Mornet, Luce Vander Elst, Sophie Laurent, Christine Jérôme* and Etienne Duguet*




Figure S1. FT-IR spectrum (a) and ¹H NMR spectrum (b) of mPEG₁₀₀₀-OH and mPEG₁₀₀₀-COOH




Figure S2. FTIR spectrum of the γ -Fe₂O₃@MSNPs before and after PEGylation (a); size distribution diagrams of the γ -Fe₂O₃@MSNPs before (black) and after (red) PEGylation from DLS analyses (b); and TEM image of the γ -Fe₂O₃@MSNPs with lower magnification (c, scale bar: 1000 nm) and (d, scale bar: 500 nm).




Figure S3. DSC (a) and TGA (b) curves of the TD/DOX-loaded $\gamma\text{-Fe}_2\text{O}_3\text{@MSNPs}$




Figure S4. Release profiles of DOX from the DOX-loaded $\gamma\text{-Fe}_2\text{O}_3\text{@MSNPs}$ (without TD as gatekeepers, *DLC* and *DLE* of *ca.* 11.6 wt. % and 25.1 %) at different temperatures. The cumulative release was presented as mean value \pm standard deviation ($n = 3$), and the solid lines just serve to guide the eyes.




Figure S5. Cytotoxicity profiles of the $\gamma\text{-Fe}_2\text{O}_3\text{@MSNPs}$ before CTAB extraction against the melanoma MEL-5 cell lines via the MTS assay, with different incubation concentrations for different periods at 37 °C. Untreated cells were taken as a control (100% viability), and percentage cell viabilities were all expressed relative to the control. Results were all presented as mean value \pm standard deviation ($n = 5$).




Figure S6. Representative TEM image of the treated MEL-5 cells after 12-h incubation with $\gamma\text{-Fe}_2\text{O}_3\text{@MSNPs}$ (100 $\mu\text{g/mL}$) at 37 °C (scale bar: 2 μm). Small dots marked with arrows refer to the internalized $\gamma\text{-Fe}_2\text{O}_3\text{@MSNPs}$.




Figure S7. Cytotoxicity profiles of DOX with different concentrations against the MEL-5 cell line determined via the MTS assay at 37 °C (a) and 40 °C (b), respectively. Percentage viabilities of the treated MEL-5 cells were expressed relative to the untreated cells, which were taken as a control (100% viability), results are all presented as mean value \pm standard deviation ($n = 5$).




Figure S8. Cytotoxicity profiles of the TD-loaded $\gamma\text{-Fe}_2\text{O}_3@$ MSNPs (without DOX uploaded) against the MEL-5 cell line at 40 °C (a) or 37/40 °C heating off/on cycles (b). Percentage cell viabilities of the treated MEL-5 cells were expressed relative to the untreated cells, which were taken as a control (100% viability), results are all presented as mean value \pm standard deviation ($n = 5$).




Figure S9. CLSM images of the MEL-5 cells after 24-h incubation with the FITC-labelled DOX-loaded γ -Fe₂O₃@MSNPs (100 μ g/mL, without TD as gatekeepers) at 37 °C: (1) nuclei stained with DAPI (blue), (2) FITC (green), (3) DOX (red), (4) merged image of (1), (2) and (3).




Figure S10. Cytotoxicity profiles of the TD/DOX-loaded γ -Fe₂O₃@MSNPs against MEL-5 cells under multiple heating off (37°C)/on (40°C) cycles with a time interval of 12 h; percentage cell viabilities of the treated MEL-5 cells were expressed relative to the untreated cells (control, 100% viability), and all results were presented as mean value \pm standard deviation (n = 5).